Close Menu

RareCyte

The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.

The Seattle-based firm's PickSeq platform integrates cell imaging and extraction tools for downstream RNA enrichment, sequencing, and targeted biomarker discovery.

The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.